| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Bone morphogenetic protein receptor type-1B;BMP type-1B receptor;BMPR-1B;2.7.11.30;CDw293;BMPR1B; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | A synthetic peptide corresponding to a sequence in the middle region of human BMPR1B, different from the related rat and mouse sequences by one amino acid. |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Target | |
| UniProt # |
Overview
Anti-BMPR1B Antibody Picoband® is an antibody targeting BMPR1B. Common applications include WB, IHC, Flow Cytometry, ELISA. Key specifications include host: Rabbit; clonality: Polyclonal; isotype: Rabbit IgG; reactivity: Human,Mouse,Rat; observed MW: 22 kDa; calculated MW: 56930 MW.
Boster Bio Anti-BMPR1B Antibody catalog # PA2017. Tested in WB applications. This antibody reacts with Human, Mouse, Rat. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.
Key elements and design rationale
- Target: BMPR1B — Bone morphogenetic protein receptor type-1B
- Antibody format: Host: Rabbit; Clonality: Polyclonal; Isotype: Rabbit IgG
- Species reactivity: Human,Mouse,Rat
- Molecular weight guidance: Observed: 22 kDa; Calculated: 56930 MW
Specificity note: No cross reactivity with other proteins.
Biological background
Protein function (datasheet): On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for BMP7/OP-1 and GDF5. Positively regulates chondrocyte differentiation through GDF5 interaction (By similarity). .
Scientific background (datasheet): BMPR1B (Bone Morphogenetic Protein Receptor Type IB), also known as ALK6, is a protein which in humans is encoded by the BMPR1B gene. BMPR1B is a member of the bone morphogenetic protein (BMP) receptor family of transmembrane serine/threonine kinases. The ligands of this receptor are BMPs, which are members of the TGF-beta superfamily. BMPs are involved in endochondral bone formation and embryogenesis. These proteins transduce their signals through the formation of heteromeric complexes of 2 different types of serine (threonine) kinase receptors: type I receptors of about 50-55 kD and type II receptors of about 70-80 kD. Type II receptors bind ligands in the absence of type I receptors, but they require their respective type I receptors for signaling, whereas type I receptors require their respective type II receptors for ligand binding. By analysis of a monochromosome hybrid mapping panel and by FISH, Astrom et al. (1999) mapped the BMPR1B gene to chromosome 4q22-q24. Ide et al. (1997) compared BMP receptor expression in normal and cancerous prostate tissues. While BMPR1A and BMPR2 were expressed at similar levels in all prostate tissues, BMPR1B was expressed at a significantly reduced level in cancerous prostate tissue.
Cellular localization (datasheet): Membrane; Single-pass type I membrane protein.
Tissue details (datasheet): Synthesized exclusively by adipocytes and secreted into plasma.
Sequence similarities (datasheet): Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. TGFB receptor subfamily.
Research relevance and current trends
- Commonly studied in contexts related to Cytoskeleton/ECM,Epigenetics and Nuclear Signaling,Extracellular Matrix,Growth Factors/Hormones,Mesenchymal Stem Cells,Nuclear Signaling,Nuclear Signaling Pathways,Protein Phosphorylation,Ser/Thr Kinases,Signal Transduction,Signaling Pathway,Stem Cells,Structures,Surface Molecules,TGF Beta.
- Supports comparative expression analysis across conditions, genotypes, or treatments when paired with appropriate controls.
- Useful for confirming target presence and subcellular distribution using orthogonal readouts (e.g., microscopy vs. immunoblotting).
Common research applications
- Western blot (WB): Compare relative target abundance and apparent size/isoforms across samples; interpret bands in light of expected MW and potential PTMs.
- ELISA: Measure target abundance in compatible matrices using a standard-curve readout; ensure dilution linearity and appropriate controls.
- Immunohistochemistry (IHC): Assess tissue distribution and cell-type patterns; interpret staining with appropriate negative controls and antigen context.
- Flow cytometry: Quantify target-positive populations in single-cell suspensions; pair with viability and isotype/FMO controls conceptually.
Notes for experimental interpretation
- Consider isoforms, post-translational modifications, and processing that can shift apparent molecular weight or localization.
- Cross-reactivity (datasheet): No cross-reactivity with other proteins
- Use appropriate positive and negative controls (e.g., KO/KD, blocking peptide, or isotype controls) to support specificity interpretation.
As a polyclonal antibody, this reagent may recognize multiple epitopes on the target, which can improve detection robustness but may require careful specificity controls.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.